Stock Detail
ALEXION PHARMACEUTICALS INC
Sector: Biotechnology
Latest Quote @ Sat May 5 20:56:42 (15 min delayed)
| N/A |
N/A |
$99.17 |
-0.71 |
-0.71% |
|
Last Day's Data
| $99.17 |
$99.71 |
$0.00 |
0.00% |
0.00 |
$99.88 |
| $98.83 |
$98.04 |
684,979.00 |
19.35B |
1.59M |
68.05 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 100.64 |
99.90 |
98.97 |
98.23 |
97.30 |
Stock Profile
Alexion Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of biologic therapeutic products for the treatment of severe diseases. It develops therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases, and cancer; and additional antibody therapeutics for other medical needs. The company primarily develops two lead product candidates, eculizumab and pexelizumab, which address specific diseases that arise when the human immune system produces inflammation in the human body. Eculizumab is in phase III clinical development for treatment of Paroxysmal Nocturnal Hemoglobinuria, a chronic hematologic disease. Pexelizumab is in clinical development for the reduction of the incidence of death, myocardial infarction or heart attack, and other complications associated with coronary artery bypass graft surgery; and for acute myocardial infarction. Alexion Pharmaceuticals has a strategic alliance with Procter and Gamble Pharmaceuticals for the development of pexelizumab. The company was co-founded by Leonard Bell, Stephen P. Squinto, Scott A. Rollins, and Joseph A. Madri in 1992. Alexion Pharmaceuticals is headquartered in Cheshire, Connecticut.
